(Press-News.org) At a glance:
Researchers have created an AI tool called EVE-Vax that can predict and design viral proteins likely to emerge in the future.
For SARS-CoV-2, panels of these “designer” proteins triggered similar immune responses as real-life viral proteins that emerged during the pandemic.
EVE-Vax could give scientists valuable clues to help them develop vaccines that protect against future versions of rapidly evolving viruses.
Effective vaccines dramatically changed the course of the COVID-19 pandemic, preventing illness, reducing disease severity, and saving millions of lives.
However, five years later, SARS-CoV-2 is still circulating, and in the process, evolving into new variants that require updated vaccines to protect against them.
But it takes time to design, manufacture, and distribute a new vaccine, which raises an important question: How can scientists create vaccines for versions of the virus that haven’t happened yet?
One solution comes from a predictive AI model called EVE-Vax built by a team of scientists at Harvard Medical School, the HMS-led Massachusetts Consortium on Pathogen Readiness (MassCPR), and other institutions.
The new model, described May 8 in Immunity, uses evolutionary, biological, and structural information about a virus to predict and design surface proteins likely to occur as the pathogen mutates. The researchers successfully applied EVE-Vax to SARS-CoV-2, designing viral proteins that elicited similar immune responses as the actual proteins that evolved during the COVID-19 pandemic.
The research, which was supported in part by federal funding, suggests that the model provides valuable information about the future evolution of a virus and can be used to create panels of “designer” proteins to evaluate the future protection of vaccines. The researchers hope that the model will eventually help scientists develop better vaccines to combat viral outbreaks and pandemics caused by rapidly mutating viruses.
“We show that if you can see where a virus is evolving ahead of time, you can begin to make future-proof vaccines,” said first author Noor Youssef, a scientific lead for the Predictive Modeling for Vaccine Design group in the Marks lab at HMS.
The evolution of EVE
Over a decade ago, study co-senior author Debora Marks, professor of systems biology in the Blavatnik Institute at HMS, and her lab began exploring whether they could use millions of years of evolutionary genetic information to make predictions about the structure and function of proteins.
In a 2021 paper, the researchers described an AI model they created based on this idea. The model, called EVE (evolutionary model of variant effect), uses large-scale evolutionary data across species to predict whether proteins will be functional. When applied to humans, EVE was able to interpret gene variants as benign or disease-causing.
As the COVID-19 pandemic unfolded, Marks and her team adapted their model to predict viral behavior.
They built EVEscape, which applied EVE’s powers of protein prediction to viral proteins. In a 2023 paper, the scientists showed that had EVEscape existed at the start of the COVID-19 pandemic, it would have predicted the most frequent SARS-CoV-2 mutations and spotted the variants of greatest concern that were most likely to cause a spike in human infections.
The success of EVEscape led the researchers to wonder whether their model could also forecast the future evolution of rapidly evolving viruses such as SARS-CoV-2.
Vaccines for such viruses are updated annually, which requires scientists to make an educated guess up to a year in advance about how viral proteins will evolve. This can lead to a mismatch between the predicted version of a virus used to design the vaccine and the actual version that ends up circulating. The gap between prediction and reality can cause vaccines to be less effective than they would have been if the versions matched more closely.
To solve this problem, the researchers developed EVE-Vax, a model that predicts and designs viral proteins that can be used to inform vaccine development ahead of time.
“We wanted to see if we could use our methods to create brand-new proteins that would be functional and would have the same immune response that we see with real viruses,” Youssef said.
Predicting SARS-CoV-2’s future maneuvers
In their latest research, the scientists used EVE-Vax to design 83 brand-new versions of the “spike” protein on SARS-CoV-2, which is the main surface protein the virus uses to infect human cells. Each new version of the spike protein had a different combination of up to ten mutations.
To test the effect of the AI-designed proteins, researchers teamed up with experimental colleagues and co-senior authors Jeremy Luban, professor of molecular medicine at UMass Chan Medical School; Jacob Lemieux, HMS assistant professor of medicine at Massachusetts General Hospital; and Michael Seaman, HMS associate professor of medicine at Beth Israel Deaconess Medical Center. The scientists performed experiments in lab dishes using safe, nonreplicating versions of SARS-CoV-2 engineered for the research. The experiments confirmed that viruses harboring the “designer” spike proteins infected human cells and elicited immune responses that largely matched the real-life immune responses to the virus at five different timepoints during the COVID-19 pandemic.
“The fundamental insight here is that evolution tells you what’s possible for the virus and its proteins to do and what might happen in the future,” Marks said.
Finally, the researchers showed that they could easily and cheaply engineer hundreds of new spike proteins that could be readily incorporated into vaccine development for SARS-CoV-2.
“Traditional vaccine design uses all sorts of different methods, but nobody’s used this approach before,” Marks said. “EVE-Vax opens a new field of potential application and design for vaccines.”
For example, the researchers showed that with EVE-Vax, they could have predicted that there would be considerable immune escape from the COVID-19 booster vaccine targeting the Omicron variant — knowledge that would have clued in scientists to build the booster differently.
“With EVE-Vax, we can predict the immune response, instead of just what the mutations on a virus will be, which is more useful in real-world situations,” Marks said.
The team is now broadening EVE-Vax to other viruses, including avian influenza, a growing problem in the United States and worldwide.
One key advantage of the model, the researchers noted, is that it can work with limited information, which opens it up for understudied viruses such as Lassa and Nipah, as well as newly emerging viruses.
Ultimately, the team hopes that EVE-Vax will give scientists critical information about the various ways in which a virus is likely to evolve, enabling them to design vaccines that protect against future versions of the pathogen.
Authorship, funding, disclosures
Additional authors on the paper include Sarah Gurev, Fadi Ghantous, Kelly Brock, Javier Jaimes, Nicole Thadani, Ann Dauphin, Amy Sherman, Leonid Yurkovetskiy, Daria Soto, Ralph Estanboulieh, Ben Kotzen, Pascal Notin, Aaron Kollasch, Alexander Cohen, Sandra Dross, Jesse Erasmus, Deborah Fuller, and Pamela Bjorkman.
Funding for the work was provided by the Coalition for Epidemic Preparedness Innovations (CEPI), MassCPR, and the National Institutes of Health (R37 AI147868).
Marks is an advisor for Dyno Therapeutics, Octant, Jura Bio, Tectonic Therapeutic, and Genentech and is a cofounder of Seismic Therapeutic.
END
Building vaccines for future versions of a virus
AI model EVE-Vax provides clues about how a virus may evolve and the immune response it could provoke
2025-05-08
ELSE PRESS RELEASES FROM THIS DATE:
Incidence of several early-onset cancers increased between 2010 and 2019
2025-05-08
PHILADELPHIA – In the United States, breast, colorectal, endometrial, pancreatic, and kidney cancers are becoming increasingly common among people under age 50, according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research (AACR).
The findings may have implications for early-onset cancer prevention and screening efforts, the researchers noted.
Early-onset cancers, defined in this study as those diagnosed in individuals under age 50, are rising in incidence for reasons that remain unclear, according ...
The road to lenacapavir, a breakthrough HIV treatment
2025-05-08
In the hunt for a remedy, when the baton is passed from dedicated academic scientists to an innovative company to trusted community advocates, outcomes for society can be especially powerful.
Today, thanks to that sequence of contributions, the first HIV drug to offer long-lasting protection from infection — eliminating the need for people to take a daily pill — exists. For their role in ensuring that drug, lenacapavir, came to life and to market, the AAAS Mani L. Bhaumik Breakthrough of the Year Award is being awarded to Wesley Sundquist, chair of the University of Utah Department of Biochemistry; Moupali Das, vice president, Clinical Development, HIV Prevention ...
Engineering an antibody against flu with sticky staying power
2025-05-08
COLUMBUS, Ohio – Scientists have engineered a monoclonal antibody that can protect mice from a lethal dose of influenza A, a new study shows. The new molecule combines the specificity of a mature flu fighter with the broad binding capacity of a more general immune system defender.
The protective effect was enhanced by delivering the antibody in a nasal spray that disperses these molecules throughout the respiratory tract, where they stick to the slippery mucus lining to lie in wait for invading viral particles.
The ...
Is AI truly creative? Turns out creativity is in the eye of the beholder
2025-05-08
What makes people think an AI system is creative? New research shows that it depends on how much they see of the creative act. The findings have implications for how we research and design creative AI systems, and they also raise fundamental questions about how we perceive creativity in other people.
‘AI is playing an increasingly large role in creative practice. Whether that means we should call it creative or not is a different question,’ says Niki Pennanen, the study’s lead author. Pennanen is researching AI systems at Aalto University and has a background in psychology. ...
Community science helps reveal population growth among SoCal’s endangered giant sea bass
2025-05-08
(Santa Barbara, Calif.) — Nicknamed the “king of the kelp forest,” giant sea bass are among scuba divers’ favorite characters to spot off the California Coast. But very few of these charismatic fish remain.
A team led by researchers at UC Santa Barbara has conducted the first direct population estimate of this critically endangered species in Southern California. Using photos sourced from the diving community, they found slightly more than 1,200 adult giant sea bass within Southern California waters from 2015 to 2022. The results, published in the Marine Ecology Progress Series represent an increasing trend in their numbers, suggesting ...
FAU CARD releases free water safety guide for children with Autism
2025-05-08
Drowning is the leading cause of unintentional death for children aged 1 to 4 in Florida, and children with autism face even greater danger – many times more likely to drown than their neurotypical peers. One key factor behind this alarming statistic is wandering, also known as elopement. Nearly 50% of children with autism will wander from a safe environment at some point. These incidents can happen in a split second and often lead to children being drawn to nearby water sources such as pools, ponds or canals – many of which are unprotected.
Children ...
Enhanced DLP-based one-step 3D printing of multifunctional magnetic soft robot
2025-05-08
In a research paper, scientists from the Tsinghua University proposed a novel enhanced Digital Light Processing (DLP) 3D printing technology, capable of printing composite magnetic structures with different material sin a single step. Furthermore, a soft robot with a hard magnetic material-superparamagnetic material composite was designed and printed.
The new research paper, published Feb. 26 in the journal Cyborg and Bionic Systems, introduces a soft robot based on DLP 3D printing technology, which presents extensive potential for the design and manufacturing of multifunctional soft robots.
According to Wang, "various ...
Discovery opens up for new ways to treat chlamydia
2025-05-08
Researchers at Umeå University, Sweden, and Michigan State University, USA, have discovered a type of molecule that can kill chlamydia bacteria but spare bacteria that are important for health. The discovery opens the door for further research towards developing new antibiotics against chlamydia, the world's most common bacterial sexually transmitted disease with 130 million cases a year.
"No one should have to live with chlamydia. But the problem is that the treatments we have today do not distinguish between dangerous and friendly bacteria. A growing problem is ...
Evaluating the safety and efficacy of a smallpox vaccine for preventing mpox
2025-05-08
In recent years, the world has seen a surge in new and deadly infectious diseases, posing a major threat to global health. Outbreaks of COVID-19, H1N1 (swine flu), Ebola, Zika, and monkeypox are a stark reminder of our vulnerability. While some of these viruses are new and relatively unknown, others, like the monkeypox virus (mpox virus or MPXV) have been around since the 1970s but have been endemic to parts of Africa. However, the recent global outbreak of mpox—caused by a newly identified variant that is more infectious than previous strains—has raised concerns across the world, ...
HIV drugs offer ‘substantial’ Alzheimer’s protection, new research indicates
2025-05-08
UVA Health scientists are calling for clinical trials testing the potential of HIV drugs called NRTIs to prevent Alzheimer’s disease after discovering that patients taking the drugs are substantially less likely to develop the memory-robbing condition.
The researchers, led by UVA’s Jayakrishna Ambati, MD, previously identified a possible mechanism by which the drugs could prevent Alzheimer’s. That promising finding prompted them to analyze two of the nation’s largest health insurance databases ...
LAST 30 PRESS RELEASES:
Global Virus Network meeting unites Caribbean and Latin America to tackle emerging viral threats
MD Anderson Research Highlights for May 8, 2025
Study of Türkiye gold mine landslide highlights need for future monitoring
Researchers find new defense against hard-to-treat plant diseases
Characterization of research grant terminations at the National Institutes of Health
New study: high efficiency of severe thalassemia prevention with HTS based carrier screening
AI-designed DNA controls genes in healthy mammalian cells for first time
Veterans with depression have increased risk of heart failure: Study
Maternal cardiometabolic risk factors in pregnancy and offspring blood pressure at ages 2 to 18
Depression and heart failure in US veterans
Experiences of care and gaslighting in patients with vulvovaginal disorders
Vitamin supplements slow down the progression of glaucoma
Physics: Eggs less likely to crack when dropped side-on
Study links maternal health risks during pregnancy to higher blood pressure in children
Building vaccines for future versions of a virus
Incidence of several early-onset cancers increased between 2010 and 2019
The road to lenacapavir, a breakthrough HIV treatment
Engineering an antibody against flu with sticky staying power
Is AI truly creative? Turns out creativity is in the eye of the beholder
Community science helps reveal population growth among SoCal’s endangered giant sea bass
FAU CARD releases free water safety guide for children with Autism
Enhanced DLP-based one-step 3D printing of multifunctional magnetic soft robot
Discovery opens up for new ways to treat chlamydia
Evaluating the safety and efficacy of a smallpox vaccine for preventing mpox
HIV drugs offer ‘substantial’ Alzheimer’s protection, new research indicates
Common lung bacteria team up to evade immune defenses
Eating ultra-processed foods may harm your health
Major US cities are sinking
New study traces sharp regional shifts in ischemic heart disease burden — a global warning signal
Too fast to see
[Press-News.org] Building vaccines for future versions of a virusAI model EVE-Vax provides clues about how a virus may evolve and the immune response it could provoke